ReviewSurgical pathology clinics2021
Polymorphous Adenocarcinoma.
Review in Surgical pathology clinics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The effects of adjuvant radiotherapy on survival outcomes in polymorphous adenocarcinoma: a retrospective cohort study.Translational cancer research · 2026Article
- Clinical-Pathological profile of head and neck cancers other than squamous cell carcinoma: A retrospective 20-year follow-up study.Journal of clinical and experimental dentistry · 2025Article
- Polymorphous adenocarcinoma: a review of the literature and presentation of a case in an uncommon anatomical area.Medicine and pharmacy reports · 2025Article
- Salivary Gland Cancers in the Era of Molecular Analysis: The Role of Tissue and Liquid Biomarkers.Cancers · 2025Review
- A case series of adenomyoepithelioma of the breast with a case of malignant adenomyoepithelioma misinterpreted as polymorphous adenocarcinoma.AME case reports · 2025Article
- Diagnostic Dilemma of Palatal Lesions: Polymorphous Adenocarcinoma (PAC) and its Insight into Updated Molecular Findings.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024Article
- Review
- A Novel Gene Fusion YLPM1::PRKD1 Identified in a Cribriform Subtype of Polymorphous Adenocarcinoma.Head and neck pathology · 2024Article
- Review
- Article
- [Salivary gland tumors-an overview : Advances in molecular characterization: Part II].Pathologie (Heidelberg, Germany) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Polymorphous adenocarcinoma (PAC) is typically originated from the minor salivary glands and is characterized by cytology uniformity and architectural diversity. PAC commonly harbors PRKD1 E710D mutation. PAC has an excellent prognosis. However, greater than or equal to 10% papillary or greater than or equal to 30% cribriform pattern is an independent adverse prognostic factor. Cribriform adenocarcinoma of salivary gland (CASG) is a controversial entity that is considered within the same histologic spectrum of PAC in current classification schemes; however, it is regarded by some pathologists as a separate entity. CASG shows a propensity to base of tongue location, a lobulated growth pattern, a predominant solid/cribriform architecture, and a high frequency of PRKD1/2/3 fusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.